TABLE 2.
Physical delivery of CRISPR/Cas systems.
| Approaches | Delivery strategies | CRISPR/Cas systems | Target genes | Target cells/tissues | Species/diseases | References |
|---|---|---|---|---|---|---|
| Microinjection | in vitro | Cas9 mRNA and sgRNAs | Ppar-γ, Rag1 | One-cell embryos | Cynomolgus monkey | Niu et al. (2014) |
| in vitro | Cas9 mRNA and sgRNAs | APOE, B2M, PRF1, and PRKDC | Fertilized eggs | Rat | Ma et al. (2014) | |
| in vitro | Cas9 mRNA and sgRNAs | Gal4 | Embryos | Zebrafish | Kimura et al. (2014) | |
| in vitro | Cas9 mRNA and sgRNAs | APOE, CD36, CFTR, LDLR, apoC-III, SCARB1, LEP, LEP-R, RyR2 | Embryos | Rabbits | Yang et al. (2014) | |
| in vitro | Cas9 mRNA and sgRNAs | MSTN | Zygotes | Sheep | Crispo et al. (2015) | |
| in vitro | Cas9 protein and sgRNA | - | Embryos | Xenopus laevis | Corkins et al. (2022) | |
| Electroporation | in vitro | CRISPR/Cas9 plasmid | APPSwe, PSEN1M146V | iPS cells | Human | Paquet et al. (2016) |
| in vitro | CRISPR/Cas9 plasmid | exon 45–55 mutation hotspot region | Myoblasts | DMD | Ousterout et al. (2015) | |
| ex vivo | CRISPR/Cas9 plasmid | PD-1 | Human primary T cells | Cancer | Su et al. (2016) | |
| ex vivo | Cas9/sgRNA RNP | TGFBR2, HPRT1 | Human NK Cells | - | Naeimi et al. (2018) | |
| In vivo | Cas9/sgRNA RNP | Sox2, GFP | - | Axolotl | Fei et al. (2016) | |
| in vivo | Cas9/sgRNA RNP | exon80 | Skin | Mouse | Wu et al. (2017b) | |
| Hydrodynamic injection | in vivo | CRISPR/Cas9 plasmid | HBV | Hepatoma cells | Transgenic mouse | Zhu et al. (2016) |
| in vivo | CRISPR/Cas9 plasmid | Pten, p53 | Liver | Mouse | Xue et al. (2014) | |
| Membrane deformation | in vitro | CRISPR/Cas9 plasmid | GFP, NUAK2, AAVS1 | 293T, MCF7, SUM159, SU-DHL-1, AB2.2 | Human, mouse | Han et al. (2015) |
| Sonoporation | in vitro | Cas9/sgRNA RNP | GFP | B16F10 | Mouse | Hansen-Bruhn et al. (2018) |
| Lance array nanoinjection | in vitro | CRISPR/Cas9 plasmid | GFP | HeLa | Human | Sessions et al. (2016) |
Notes: Ppar-γ: peroxisome proliferator-activated receptor; Rag1: recombination activating 1; APOE: apolipoprotein; B2M: beta-2-microglobulin; PRF1: perforin 1; PRKDC: protein kinase, DNA-activated, catalytic subunit; GAL4: galactose-responsive transcription factor; CD36: cluster of differentiation 36; CFTR: cystic fibrosis transmembrane conductance regulator; LDLR: low-density lipoprotein receptor; apoC-III: apolipoprotein C-III; SCARB1: scavenger receptor class B,member1; LEP: leptin; LEP-R: leptin receptor; RyR2: ryanodine receptor 2; MSTN: myostatin; iPS: pluripotent stem cells; APPSwe: amyloid precursor protein; PSEN1M146V: presenilin 1; DMD: duchenne muscular dystrophy; PD-1: programmed death-1; TGFBR2: TGF-beta type II, receptor; HPRT1: hypoxanthine phosphoribosyltransferase 1; HBV: hepatitis B virus; GFP: green fluorescent protein; RNP: ribonucleoprotein.